Valuation: Agenus Inc.

Market Cap 127M 112M 103M 95.96M 181M 12.11B 185M 1.24B 480M 5.95B 478M 468M 20.7B P/E 2026 *
3.9x
P/E 2027 * -17x
Enterprise Value 127M 112M 103M 95.96M 181M 12.11B 185M 1.24B 480M 5.95B 478M 468M 20.7B EV / Sales 2026 *
0.69x
EV / Sales 2027 * 0.97x
Free-Float
93.3%
Yield 2026 *
-
Yield 2027 * -
1 day+9.31%
1 week+14.90%
Current month+9.64%
1 month-3.59%
3 months-1.32%
6 months+3.87%
Current year+6.85%
1 week 2.85
Extreme 2.85
3.36
1 month 2.85
Extreme 2.85
3.52
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
38.6
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Chief Executive Officer

5,364 0.0129%
06-12Free

Chief Executive Officer

4,925 0.0118%
05-29Free

Chief Executive Officer

4,644 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
+9.31%+14.90%-30.68%-88.96% 127M
+3.08%+6.47%-0.25%+6.27% 47.18B
-0.88%+9.42%+403.58%+592.40% 39.82B
+5.60%+10.31%+25.92%-7.38% 32.25B
+2.49%+5.08%+18.78%+61.02% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
-0.27%+12.07% - - 16.57B
+3.55%+7.01%+70.91%+129.56% 15.12B
-0.15%+2.15%+12.64%+17.55% 13.69B
-0.99%+2.35%+96.08%+90.64% 13.1B
Average +2.22%+6.99%+67.98%+92.44% 23.41B
Weighted average by Cap. +1.74%+7.40%+93.55%+136.57%

Financials

2026 *2027 *
Net sales 185M 162M 149M 139M 262M 17.56B 268M 1.8B 696M 8.62B 693M 678M 30B 131M 115M 106M 98.99M 187M 12.5B 190M 1.28B 495M 6.13B 494M 483M 21.35B
Net income 46M 40.39M 37.18M 34.64M 65.33M 4.37B 66.66M 447M 173M 2.15B 173M 169M 7.47B -9.9M -8.69M -8M -7.46M -14.06M -941M -14.35M -96.23M -37.28M -462M -37.17M -36.37M -1.61B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
01/07/26 $3.360 +9.80% 384,724
30/06/26 $3.060 -2.86% 644,548
29/06/26 $3.150 +3.96% 947,439
26/06/26 $3.030 +5.21% 5,006,329
25/06/26 $2.880 -1.37% 594,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.060USD
Average target price
15.50USD
Spread / Average Target
+406.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock